All In Biotech

Drug Trial Radar · NCT06321302

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

CRIMSON: A Multicentre, Randomised, Sham-controlled (and Active Controlled in the USA), Double-masked, 72-week Trial to Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal BI 764524 in Patients With Moderate to Severe Non-proliferative Diabetic Retinopathy

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

May 15, 2024

Primary completion

Mar 5, 2027

Study completion Aug 20, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Participants in groups 1, 2, and 3 get BI 764524. Over 1 year, they get a different number of injections of the same dose of BI 764524 injected into 1 eye. During some visits, participants may get a sham control, which is done like an eye injection but without a needle, so that participants will not know how many injections of BI 764524 they received. Participants in group 4 only get a sham control. Participants in group 5 (only in the USA) get aflibercept or sham injections during some visits. Aflibercept is a medicine already used to treat diabetic retinopathy. Participants are in the study for one and a half years. During this time, they visit the study site at least 16 times. During this time, doctors regularly do eye exams and visual tests to assess the severity of participants' eye condition. After 1 year of treatment, researchers look at the number of participants with eye improvements. To do so, they compare eye damage and certain severe eye problems between the groups of participants. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Diabetic Retinopathy

Interventions

  • BI 764524Drug

    BI 764524

  • Sham comparator to BI 764524Drug

    Sham comparator to BI 764524

  • Aflibercept (Eylea®) - US onlyDrug

    Aflibercept (Eylea®) - US only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52 as assessed by Ultra-widefield colour fundus photography (UWF-CFP) images (within the 7-field grid)Time frame: At baseline and at Week 52

Locations

90 sites in 9 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona · Active not recruiting

  • California Retina Consultants-Bakersfield-65523

    Bakersfield, California · Active not recruiting

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Active not recruiting

  • Retinal Diagnostic Center

    Campbell, California · Completed

  • The Retina Partners

    Encino, California · Active not recruiting

  • Lugene Eye Institute

    Glendale, California · Active not recruiting

  • Retina Associates of Southern California

    Huntington Beach, California · Active not recruiting

  • Byers Eye Institute

    Palo Alto, California · Completed

  • California Eye Specialists Medical Group Inc

    Pasadena, California · Active not recruiting

  • Retinal Consultants Medical Group

    Sacramento, California · Active not recruiting

  • Retinal Consultants Medical Group

    Sacramento, California · Active not recruiting

  • California Retina Consultants-Santa Maria-65510

    Santa Maria, California · Active not recruiting

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California · Active not recruiting

  • Colorado Retina Associates

    Lakewood, Colorado · Active not recruiting

  • Retina Group of New England, PC

    Waterford, Connecticut · Completed

  • Florida Retina Institute

    Jacksonville, Florida · Recruiting

  • Florida Retina Consultants

    Lakeland, Florida · Active not recruiting

  • East Florida Eye Institute

    Stuart, Florida · Active not recruiting

  • Center for Retina and Macular Disease

    Winter Haven, Florida · Active not recruiting

  • Retina Consultants Of Hawaii

    ‘Aiea, Hawaii · Active not recruiting

  • Maine Eye Center

    Portland, Maine · Active not recruiting

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland · Active not recruiting

  • Deep Blue Retina Clinical Research PLLC

    Southaven, Mississippi · Active not recruiting

  • NJRetina

    Teaneck, New Jersey · Active not recruiting

  • Long Island Vitreoretinal Consultants

    Great Neck, New York · Completed

  • Retina Vitreous Surgeons of Central NY, PC

    Liverpool, New York · Active not recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Active not recruiting

  • EyeHealth Northwest

    Portland, Oregon · Completed

  • Charleston Neuroscience Institute - Ladson

    Ladson, South Carolina · Completed

  • Tennessee Retina

    Nashville, Tennessee · Active not recruiting

  • Austin Retina Associates

    Austin, Texas · Active not recruiting

  • Retina Research Center, PLLC

    Austin, Texas · Active not recruiting

  • Austin Clinical Research, LLC

    Austin, Texas · Active not recruiting

  • Retina Consultants of Texas

    Katy, Texas · Active not recruiting

  • Valley Retina Institute, PA

    McAllen, Texas · Completed

  • Austin Retina Associates

    Round Rock, Texas · Completed

  • Medical Center Ophthalmology Associates

    San Antonio, Texas · Active not recruiting

  • Retina Consultants of Texas

    San Antonio, Texas · Active not recruiting

  • Retina Consultants of Texas - Schertz

    Schertz, Texas · Completed

  • Retina Associates of Utah

    Salt Lake City, Utah · Recruiting

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.